23 March 2018 - Review will be subject of October CTAF meeting; open input now being accepted until 9 April.

The ICER today announced plans to assess the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterised by attacks of deep tissue swelling within the skin and/or mucosa. The report is set to be reviewed during an October 2018 public meeting of the California Technology Assessment Forum, one of ICER’s three independent evidence appraisal committees.

ICER’s report is expected to focus on four therapies for the prevention of hereditary angioedema attacks: lanadelumab (Shire), which is currently under review by the FDA with an approval decision expected in August of 2018, and three C1 esterase inhibitors (Haegarda, CSL Behring; Cinryze, Shire; and Ruconest, Pharming). This list is tentative and subject to change.

Read ICER Announcement